# LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **glipizide** (Sulfonylureas)
- Outcome: **Renal cancer**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	268,889	200,340	108	0.54
Merative CCAE	17,862	13,533	8	0.59
Merative MDCD	2,861	1,550	<5	<3.23
Merative MDCR	1,995	1,160	5	4.31
Optum Clinformatics	22,677	16,085	17	1.06
Optum EHR	19,553	9,066	6	0.66
Veterans Affairs	19,646	17,631	19	1.08

How Reliable Are the Effect Estimates? (Objective diagnostics)

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)